Table 2 Drugs targeting lipid metabolism and their mechanisms

CD36

JC61.3

oral cancer

gastric cancer

inhibit FA and LDL protein uptake; prevents lipid droplet formation

N/A [104]

FA6.152

oral cancer

prevent lipid droplet formation

N/A [1]

SSO

cervical cancer

inhibit FA uptake

N/A [105]

FABP

SBFI-26

prostate cancer

inhibit lipogenesis

N/A [1]

BMS3094013

ovarian cancer

inhibit lipogenesis

N/A [106]

FASN

Orlistat

prostate cancer

NSCLC

induce lipid peroxidation and ferroptosis

N/A [107]

TVB-3166

lung cancer

ovarian cancer

prostate cancer

HCC

promote tumor cell apoptosis

N/A [108]

TVB-3664

colon cancer

lung cancer

promote tumor cell apoptosis

N/A [108]

TVB2640

ovarian cancer

breast cancer

reduce hepatic fat

NCT03808558

NCT02223247

NCT02980029

NCT03179904

NCT03032484

NCT03938246 [109, 117]

Fasnall

breast cancer

promote apoptosis

N/A [109]

ACLY

ECT-1002

HCC

inhibit lipogenesis

NCT05687071

NCT05683340

NCT04784442 [110]

SB-204990

ovarian cancer

inhibiting ACLY and activate the AMPK-ROS pathway

N/A [110]

ACC

PF-05221304

-

reduce liver fat

N/A [111]

ND-646

NSCLC

inhibite fatty acid synthesis

N/A [111]

ND-654

HCC

inhibit lipogenesis

N/A [112]

SCD1

A939572

lung cancer

ovarian cancer

induce endoplasmic reticulum stress; inhibit epithelial-mesenchymal transition; inhibit EGFR/PI3K/AKT signaling

N/A [113]

MF-438

NSCLC

ovarian cancer melanoma

downregulate YAP/TAZ

N/A [1]

MK-8245

-

-

NCT00972322 [117]

CAY10566

-

activate the AMPK pathway and lipophagocytosis

N/A [114]

DGAT1

A922500

cervical cancer

HCC

inhibit triglyceride synthesis

N/A [115]

AZD3988

prostate cancer

decrease TAG synthesis

N/A [1]

AZD7687

-

reduced circulating TAG

NCT01217905 [116]

DGAT2

PF-06424439

gastric cancer

breast cancer

prevents LD formation

N/A [1]

JNJ-DGAT2-A/B

-

inhibit TG synthesis

N/A [1]